Factory Supply High Purity Atovaquone CAS 95233-18-4

Product Details
Customization: Available
Type: Pharmaceutical Intermediates
Appearance: Yellow Powder
Still deciding? Get samples of US$ 20/kg
Request Sample
Gold Member Since 2022

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

to see all verified strength labels (17)
  • Factory Supply High Purity Atovaquone CAS 95233-18-4
  • Factory Supply High Purity Atovaquone CAS 95233-18-4
  • Factory Supply High Purity Atovaquone CAS 95233-18-4
  • Factory Supply High Purity Atovaquone CAS 95233-18-4
  • Factory Supply High Purity Atovaquone CAS 95233-18-4
  • Factory Supply High Purity Atovaquone CAS 95233-18-4
Find Similar Products

Basic Info.

Quality
Industrial
Certification
GMP, Hse, ISO 9001, USP, Bp
Delivery Time
Within 24 Hours After Receiving The Payment
Specification
25kg/500kg/1000kg
Trademark
Jinan Andechem
Origin
China
HS Code
29147000
Production Capacity
5ton/Month

Product Description

Factory Supply High Purity Atovaquone CAS 95233-18-4
Product Name Atovaquone
CAS No. 95233-18-4
MF C22H19ClO3
Appearance Yellow Powder
Packing 1KG/Bag
Specification BP, USP, EP
Shelf life 2 Years
Factory Supply High Purity Atovaquone CAS 95233-18-4
Factory Supply High Purity Atovaquone CAS 95233-18-4Atovaquone is an orally active antiprotozoal agent indicated for patients with mild to moderate AIDS-associated Pneumocystis carinii pneumonia who are intolerant to the fist-line therapy of trimethoprim-sulfamethoxazole. It is also under investigation as a treatment for malaria and AIDS-associated toxoplasmosis.
The hydroxynaphthoquinone atovaquone, which exhibits antimalarial and anti-Pneumocystis activity, is an electron transport inhibitor that causes depletion of the ATP pool. The primary effect is on the iron flavoprotein dihydro-orotate dehydrogenase, an essential enzyme in the production of pyrimidines. Mammalian cells are able to avoid undue toxicity by use of preformed pyrimidines. Dihydro-orotate dehydrogenase from Plasmodium falciparum is inhibited by concentrations of atovaquone that are very much lower than those needed to inhibit the Pneumocystis enzyme, raising the possibility that the antimicrobial consequences might differ in the two organisms. Although atovaquone was originally developed as a monotherapy for malaria, high level resistance readily emerges in Plasmodium falciparum when the drug is used alone. Consequently, atovaquone is now combined with proguanil.

Factory Supply High Purity Atovaquone CAS 95233-18-4Factory Supply High Purity Atovaquone CAS 95233-18-4Factory Supply High Purity Atovaquone CAS 95233-18-4Factory Supply High Purity Atovaquone CAS 95233-18-4Factory Supply High Purity Atovaquone CAS 95233-18-4

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier